What is the dosing regimen for digoxin (digitalis glycoside) intravenously in the treatment of atrial fibrillation with a digitalis-associated cardioversion response (Dacar response) in acute decompensated heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Intravenous Digoxin Dosing Regimen for Atrial Fibrillation with Dacar Response in Acute Decompensated Heart Failure

For acute decompensated heart failure with atrial fibrillation requiring a Dacar response, the recommended intravenous digoxin loading dose is 8-12 mcg/kg, with half the total dose administered initially, followed by one-quarter of the loading dose every 6-8 hours twice, targeting a serum concentration of 0.6-1.2 ng/mL. 1

Initial Loading Dose Strategy

The FDA-approved loading dose regimen for intravenous digoxin in adults with atrial fibrillation is:

  • Total IV loading dose: 8-12 mcg/kg 1
  • Administration schedule:
    • Give half the total loading dose initially
    • Then give ¼ of the loading dose every 6-8 hours twice 1

For example, in a 70 kg patient:

  • Total loading dose: 560-840 mcg
  • Initial dose: 280-420 mcg
  • Followed by two doses of 140-210 mcg each at 6-8 hour intervals

Important Administration Considerations

  • Administer the dose over at least 5 minutes to prevent systemic and coronary vasoconstriction 1
  • Avoid bolus administration due to risk of cardiovascular adverse effects 1
  • Digoxin can be administered undiluted or diluted with a 4-fold or greater volume of sterile water, normal saline, or 5% dextrose 1
  • Monitor ECG and vital signs during administration

Maintenance Dosing

After loading, the maintenance dose should be determined based on:

  • Lean body weight
  • Renal function
  • Age
  • Concomitant medications

For adults with normal renal function, the recommended intravenous maintenance dose is 2.4-3.6 mcg/kg/day given once daily 1.

Monitoring Parameters

  • Target serum concentration: 0.6-1.2 ng/mL 2
  • Serum levels >2 ng/mL are associated with toxicity 1
  • Check serum digoxin levels early during therapy, especially in patients with renal impairment 2
  • Obtain levels at least 6 hours after the last dose or just before the next scheduled dose 1
  • Monitor serum electrolytes (especially potassium, calcium, and magnesium) and renal function regularly 2

Special Considerations and Cautions

Risk Factors for Toxicity

  • Advanced age
  • Renal impairment
  • Low lean body mass
  • Electrolyte abnormalities (hypokalemia, hypercalcemia, hypomagnesemia)
  • Drug interactions (amiodarone, verapamil, diltiazem, certain antibiotics, quinidine) 2, 1

Contraindications

  • Ventricular fibrillation
  • Second or third-degree heart block without a pacemaker
  • Pre-excitation syndromes (Wolff-Parkinson-White)
  • Previous digoxin intolerance 2, 1

Signs of Toxicity

  • Cardiac arrhythmias (sinoatrial and AV block, atrial and ventricular arrhythmias)
  • Gastrointestinal symptoms (anorexia, nausea, vomiting)
  • Neurological symptoms (confusion, visual disturbances) 2, 1

Long-term Management Considerations

For long-term management after stabilization:

  • Consider switching to oral digoxin with appropriate dose adjustment (IV digoxin has 100% bioavailability vs. 60-80% for oral tablets) 1
  • In the long term, a beta-blocker, either alone or in combination with digoxin, is the preferred treatment for rate control in patients with atrial fibrillation and heart failure with reduced ejection fraction 2
  • For patients with severe heart failure symptoms, digoxin may be used in combination with beta-blockers for rate control 2

Remember that while digoxin is useful for initial control of ventricular rate in patients with rapid atrial fibrillation and may be considered in decompensated heart failure patients prior to initiation of a beta-blocker, it does not improve mortality in heart failure patients 2, 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.